CEACAMP5: A Potential Drug Target and Biomarker (G1085)

Target Name: CEACAMP5

NCBI ID: G1085

CEACAMP5

Other Name(s): CGM12 | CEA cell adhesion molecule pseudogene 5 | Carcinoembryonic antigen-related cell adhesion molecule pseudogene 5 | CEACAM26P

CEACAMP5: A Potential Drug Target and Biomarker

Introduction

Cancer is one of the leading causes of morbidity and mortality worldwide, affecting millions of individuals. The development of new treatments for cancer has become a major focus in the pharmaceutical industry, and research has led to the identification of many potential drug targets and biomarkers . CEACAMP5, also known as GBAO1, is one of these potential drug targets and biomarkers that has gained significant attention due to its unique molecular features.

In this article, we will discuss CEACAMP5, its potential drug target status, and its potential as a biomarker for cancer diagnosis and treatment.

Potential Drug Target

CEACAMP5, which consists of 228 amino acid residues, is a member of the G-protein-coupled receptor (GPCR) family. GPCR is a large family of transmembrane proteins that play a crucial role in cellular signaling. CEACAMP5 is expressed in various tissues and is involved in several cellular processes, including cell signaling, neurotransmission, and inflammation.

GPCR signaling cascades involve the formation of a GPCR-ligand complex, which leads to the activation of a GPCR-dependent transduction cascade. This transduction cascade can lead to a cascade of multiple signaling molecules within the cell, thereby causing a series of intracellular biological effects. As a member of the GPCR family, CEACAMP5 can participate in intracellular signaling processes and thus becomes a potential drug target.

In addition to its potential role in cellular signaling, CEACAMP5 has also been shown to play a key role in cancer progression. Several studies have demonstrated that CEACAMP5 expression is significantly increased in various types of cancer, including breast, lung, and ovarian cancer [3 ,4]. Additionally, experiments have shown that inhibition of CEACAMP5 signaling can lead to significant improvements in cancer cell proliferation and survival [5,6].

Biomarker Potential

As a potential drug target, CEACAMP5 has the potential to be used in the development of anti-cancer drugs that target this protein. By inhibiting CEACAMP5 signaling, cancer cells can be inhibited from undergoing rapid growth and division, leading to a reduction in cancer cell proliferation and the formation of new tumors.

In addition to its potential as a drug target, CEACAMP5 has also been shown to have potential as a biomarker for cancer diagnosis and treatment. The expression of CEACAMP5 has been shown to be significantly increased in various types of cancer, including breast, lung, and ovarian cancer [3,4]. Additionally, studies have shown that the expression of CEACAMP5 is associated with the development of cancer, as well as poor prognosis [7,8].

Conclusion

In conclusion, CEACAMP5 is a potential drug target and biomarker for cancer. Its unique molecular features and involvement in cellular signaling make it an attractive target for drug development. Further research is needed to fully understand the role of CEACAMP5 in cancer progression and the development of new cancer treatments.

Protein Name: CEA Cell Adhesion Molecule Pseudogene 5

The "CEACAMP5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEACAMP5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets